West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. (WST): 23 pipeline candidates · 5 upcoming catalysts · ~24 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
23.8 months
D/E 0.37 · 2% dilution
Lead: Phase 3
23 candidates
5 upcoming, next in ~166d
0 buys · 2 sells (180d)
A transparent, data-derived signal for West Pharmaceutical Services Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.2B
Cash
$521.4M
Quarterly Burn
$115.3M
Runway
23.8 mo
Revenue
$844.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| aln-ang3 | Phase 2 |
| ap301 | Phase 3 |
| bendamustine | Phase 3 |
| cemdisiran | Phase 3 |
| cemiplimab | Phase 2 |
| cmp-001 | Phase 2/Phase 3 |
| evinacumab | Phase 2 |
| fdc fianlimab+cemiplimab | Phase 2 |
| fianlimab | Phase 3 |
| garetosmab | Phase 2 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
751
Total value held
$17.41B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 9,366,572 | $2.35B |
| blackrock, inc. | 6,836,714 | $1.71B |
| vanguard portfolio management llc | 4,094,009 | $1.03B |
| state street corp | 3,293,778 | $825.6M |
| bank of new york mellon corp | 2,465,858 | $618.0M |
| generation investment management llp | 2,243,976 | $562.4M |
| geode capital management, llc | 1,912,455 | $477.5M |
| morgan stanley | 1,458,282 | $365.5M |
| brown advisory inc | 1,340,877 | $336.1M |
| longview partners (guernsey) ltd | 1,315,403 | $329.7M |
Showing top 10 of 751 institutional holders of West Pharmaceutical Services Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in West Pharmaceutical Services Inc.'s pipeline?
West Pharmaceutical Services Inc. (WST) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is West Pharmaceutical Services Inc.'s lead drug candidate?
West Pharmaceutical Services Inc.'s most advanced tracked candidate is aln-ang3 (Phase 2) for Diabetic Kidney Disease (DKD).
What is West Pharmaceutical Services Inc.'s next catalyst?
West Pharmaceutical Services Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis" — expected December 1, 2026.
What is West Pharmaceutical Services Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, West Pharmaceutical Services Inc. has approximately 23.8 months of cash runway.
What is West Pharmaceutical Services Inc.'s market capitalization?
West Pharmaceutical Services Inc.'s market capitalization is approximately $23.2B.
Get the full picture on West Pharmaceutical Services Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.